Roche Stock Falls as Breast Cancer Drug Fails Trial Goals
In a significant setback, Roche’s shares suffered a steep drop exceeding 7% at one point on Monday…
CERAN wrap: Roche phase III BC win seals thesis, boosts Olema
Roche AG’s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor…
Giredestrant demonstrates efficacy in early-stage breast cancer
Roche has reported positive Phase III data for its selective estrogen receptor degrader (SERD) giredestrant across multiple stages…